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demethylation observed at the highly conserved +37 
CpG site located 4 bp upstream of rs143383. Methylation 
modulates the level and direction of allelic imbalance of 
rs143383, with methylation of the +37 CpG dinucleotide 
within the sP1/sP3 binding site having an allele-specific 
effect on sP1 and sP3 binding. Furthermore, methylation 
attenuated the repressive effects of sP1, sP3 and DeaF1 
on GDF5 promoter activity. this data suggest that the dif-
ferential methylation of the +37 CpG site between osteo-
arthritic hip and knee cartilage may be responsible for the 
knee-specific effect of rs143383 on Oa susceptibility.
Introduction
Osteoarthritis is a chronic and age-associated disease that 
severely affects the function of synovial joints, principally 
the knees, hips, and hands. Oa pathogenesis involves the 
irreversible focal destruction of articular cartilage, with 
alteration in the homeostatic balance of the cartilage chon-
drocytes cells, and with accompanying changes in other joint 
tissues (Houard et al. 2013; loeser et al. 2012). Pain and dis-
ability is a common feature of the disease, with the economic 
cost of Oa estimated to be 1–2 % of gross national product 
in Western countries (McGuire et al. 2002). the incidence 
and prevalence of Oa will rise over the next few decades as 
average lifespan and obesity levels continue to increase.
twin pair and segregation studies have highlighted 
genetics as a significant risk factor for Oa, with heritabil-
ity estimates as high as 80 % at some joint sites (loughlin 
2005). Genome-wide association scans together with can-
didate gene studies have identified several genomic regions 
that harbour Oa susceptibility alleles. However, these stud-
ies rarely identify which variants are causal, and, like most 
common diseases, the identification of these alleles and 
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elucidation of the mechanism through which they increase 
disease susceptibility has proven challenging. the most 
compelling Oa risk allele, and the only one so far that is 
unambiguously shared between european and asian indi-
viduals, is the rs143383 single nucleotide polymorphism 
(snP) on chromosome 20 (reynard and loughlin 2013). In 
europeans, this association is particularly relevant to knee 
Oa compared to the other joint that has been extensively 
investigated, the hip (evangelou et al. 2009).
rs143383 is located within the 5ʹ untranslated region 
(Utr) of the growth differentiation factor 5 gene GDF5, 
whose protein is a member of the BMP subgroup of the 
tGF-β superfamily. Mutations of GDF5 are responsible for 
several human dominant monogenic disorders including Du 
Pan syndrome (szczaluba et al. 2005), Brachydactyly type 
a2 (Plöger et al. 2008) and multiple synostoses syndrome 
2 (Dawson et al. 2006), as well as the mouse brachypodism 
(bp) phenotype, all of which are characterised by musculo-
skeletal abnormalities. Mice with targeted overexpression 
of GDF5 in cartilage have a reduced chondrocyte prolifera-
tive zone and expanded pre-hypertrophic and hypertrophic 
zones of the growth plate with increased expression of dif-
ferentiation markers Ihh and Col10a1 (tsumaki et al. 1999). 
Overexpression of human GDF5 in human mesenchymal 
stem cells enhances chondrocyte differentiation and hyper-
trophy (Coleman et al. 2013), induces tenogenic differentia-
tion (tan et al. 2012) and stimulates osteogenesis and bone 
formation (Cheng et al. 2012). GDF5 plays an important 
role in postnatal joint homeostasis and repair (luyten 1997), 
and injection of recombinant human GDF5 into the nucleus 
pulposus of rabbits after anular puncture of the interverte-
bral discs is reported to have a reparative effect Chujo et al. 
2006). as well as developmental failure of the condyles and 
intraarticular knee ligament (Harada et al. 2007), GDF5 
null mice have delayed cartilage formation and wound cal-
las remodelling after tibial fracture (Coleman et al. 2011). 
GDF5 is overexpressed in articular cartilage relative to oste-
ophytic cartilage of Oa patients, suggesting that it may play 
an important role in maintaining the stable articular chon-
drocyte phenotype (Gelse et al. 2012).
rs143383 is within the GDF5 promoter and there is an 
imbalance between the expression of the C and t alleles 
of this snP, with an average of 27 % lower expression of 
the disease-associated t allele than the C allele in synovial 
joint tissues from Oa patients (southam et al. 2007; egli 
et al. 2009). the joint-wide reduction in GDF5 expres-
sion caused by this allelic expression imbalance (aeI) is 
hypothesised to underlie the Oa susceptibility mediated by 
rs143383 (southam et al. 2007). In support of this hypoth-
esis, mice with only one copy of Gdf5 have more severe 
osteoarthritic changes, including reduced subchondral 
bone and increased synovial hyperplasia, than their wild-
type littermates after mechanical or chemical induction of 
Oa (Daans et al. 2011). the t allele of rs143383 is also 
associated with several other disease phenotypes, including 
achilles tendinopathy (Posthumus et al. 2010), and con-
genital dislocation of the hip (rouault et al. 2010), high-
lighting the pleiotropic action of GDF5 and its protein in 
the development, maintenance and repair of the musculo-
skeletal system.
We have previously reported that Dna methylation reg-
ulates GDF5 expression in human cell lines and that dem-
ethylation of the GDF5 locus is associated with an increase 
in the allelic imbalance of rs143383 (reynard et al. 2011). 
In its C allele form, rs143383 creates a CpG site and is 
flanked by several non-polymorphic CpG sites, including 
one that is only four bases upstream of the snP and at posi-
tion +37 relative to the GDF5 transcription start site (tss). 
More recently, we demonstrated that the sP1, sP3, sUB1 
(also known as P15 and PC4) and DeaF1 trans-activating 
proteins bind to and differentially repress the transcription 
of the two alleles of rs143383 (syddall et al. 2013), result-
ing in the aeI that underlies the Oa susceptibility mediated 
by this snP. In our current study, we have investigated the 
interaction between genetics, Dna methylation and tran-
scription at rs143383 using cartilage from Oa patients and 
transformed human cell lines. We examined if GDF5 was 
regulated by Dna methylation in cartilage and assessed if 
this methylation was aberrant in osteoarthritic patients. We 
observed up-regulation of GDF5 expression in the cartilage 
chondrocytes after exposure to a demethylating agent and 
after the sirna knock-down of enzymes that methylate 
Dna, indicating that Dna methylation represses GDF5 
expression in this tissue. Furthermore, bisulphite pyrose-
quencing revealed that the GDF5 5ʹUtr is demethylated 
in Oa knee cartilage and that methylation of this region is 
associated with a reversal of the imbalance between the two 
alleles of rs143383. We then investigated the effect Dna 
methylation has on the binding to and repression of the 
GDF5 5ʹUtr by sP1, sP3 and DeaF1 using electropho-
retic mobility shift assays (eMsas) and luciferase assays. 
Our data demonstrate that methylation regulates GDF5 
expression in cartilage and modulates the functional effect 
of the Oa snP rs143383 by altering binding of sP1, sP3 
and DeaF1 transcriptional repressors. Our data also show 
that these effects are particularly striking for knee cartilage 
relative to hip cartilage, which may partly explain why the 
rs143383 Oa association is more pronounced at the knee.
Results
GDF5 is up-regulated in Oa cartilage
We had previously generated gene expression microarray 
data for hip cartilage from patients who had undergone 
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joint replacement surgery due to either hip Oa or a neck of 
femur (nOF) fracture (Xu et al. 2012). this latter cartilage 
serves as a non-Oa control. Our analysis of GDF5 revealed 
that the gene was up-regulated 1.9-fold in cartilage from 
Oa patients (n = 12) relative to the control nOF patients 
(n = 13; p < 0.0001, Figure s1a). We replicated this result 
by quantitative real-time PCr (qrt-PCr) analysis of 
GDF5 expression in an unrelated sample of nine nOF and 
21 Oa hip patients, with the gene again showing an up-reg-
ulation in Oa, this time 3.3-fold (p < 0.01, Fig. 1). We also 
performed GDF5 qrt-PCr on knee cartilage from 28 Oa 
patients and noted that the gene was also up-regulated in 
this tissue, 4.6-fold, compared to the non-Oa control car-
tilage (p < 0.001, Fig. 1). Overall, GDF5 showed greater 
expression in Oa than non-Oa cartilage, and this effect 
was particularly striking for the knee. no effect of age, 
gender or rs143383 genotype on the expression of GDF5 
was observed (Figure s1B-D). 
Inhibition of Dna methylation in articular chondrocytes  
is accompanied by increased expression of GDF5
We previously reported that GDF5 expression is up-
regulated in four human transformed cell lines after 
exposure to the Dna methyltransferase inhibitor 5-aza-
2′-deoxycytidine (aZa), which induced significant dem-
ethylation of the GDF5 locus in these cells (reynard et al. 
2011). to investigate if Dna methylation also regulates 
GDF5 expression in cartilage, primary human articular 
chondrocytes (HaCs) from four Oa patients were cultured 
with 5 µM aZa for three passages. GDF5 expression was 
significantly increased in HaCs from all four patients after 
aZa treatment (Fig. 2a), with the level of up-regulation 
varying between patients from 1.95-fold to 5.37-fold. to 
further examine the effect of Dna methylation on GDF5 
expression in HaCs, the Dna methyltransferase enzymes, 
which catalyse the transfer of methyl groups from s-aden-
osyl methionine to CpG dinucleotides, were depleted by 
rna interference (rnai; Fig. 2b). there was a signifi-
cant up-regulation of GDF5 after depletion of DnMt1 
(p < 0.01), which methylates hemimethylated Dna 
after Dna replication, and after depletion of the de novo 
methyltransferases DnMt3a (p = 0.02) and DnMt3B 
(p = 0.03), suggesting that these enzymes are involved in 
regulating GDF5 expression in HaCs. 
GDF5 is demethylated in Oa cartilage
the above result demonstrated that Dna methylation 
modulates GDF5 expression in cartilage, and our previ-
ous study demonstrated that methylation of the CpG island 
and 5ʹUtr significantly represses the promoter activity of 
these regions in vitro (reynard et al. 2011). We therefore 
investigated if the increased expression of GDF5 in Oa 
cartilage that we observed in Fig. 1 was due to demeth-
ylation of the GDF5 locus. We analysed the methylation 
of the CpG island and 5ʹUtr in cartilage obtained from 
nOF, Oa hip and Oa knee patients. the CpG island is 
located between −1,345 and −1,210 bp upstream of the 
GDF5 transcription start site (tss; Fig. 3a), and was sig-
nificantly demethylated in Oa hip (n = 11, p = 0.02) and 
Oa knee cartilage (n = 13, p < 0.0001) relative to non-Oa 
nOF cartilage (n = 19, Figs. 3b, s2B and s2C). Oa knee 
cartilage had the lowest levels of methylation at all nine 
CpG sites within the CpG island relative to Oa hip and 
nOF cartilage, and there was significant demethylation 
at −1,262, −1,257, and −1,253 bp CpG sites in Oa hip 
versus Oa knee cartilage (p < 0.01, Fig. 3c). the 5ʹUtr 
region spanning +37 to +106 bp downstream of the tss 
was also hypomethylated in Oa knee cartilage relative to 
nOF hip cartilage (p < 0.0001) and relative to Oa hip car-
tilage (p = 0.025; Figs. 3d, s2D and s2e), with significant 
demethylation at the +37 CpG site (Fig. 3e). no difference 
in methylation of the 5ʹUtr was observed in Oa hip carti-
lage relative to non-Oa hip cartilage at any of the non-pol-
ymorphic CpG sites within this region. In addition, meth-
ylation of the CpG site created by the C allele of rs143383 
was significantly reduced in knee cartilage relative to hip 
cartilage from individuals homozygous or heterozygous 
for the C allele (p < 0.05, Fig. 3f). Bearing in mind that 
the Oa association to rs143383 is more pronounced in 
knee than in hip Oa (evangelou et al. 2009), these two last 
observations appear highly relevant. there was no effect 
of gender or rs143383 genotype on mean methylation of 
the CpG island (Figure s2B, s2C and s2F) or the 5ʹUtr 
(Figure s2D, s2e and s2G), nor for any individual CpG 
site within these regions (data not shown). together, these 
data demonstrate that GDF5 is hypomethylated in Oa 
Fig. 1  GDF5 expression in cartilage. GDF5 expression in cartilage 
samples from nOF (n = 9), Oa hip (n = 21) and Oa knee (n = 28) 
patients was assayed by qrt-PCr and normalised to 18s. Bars repre-
sent the mean. **p < 0.01, ***p < 0.00, Mann–Whitney U test
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cartilage and this is markedly evident within the 5ʹUtr for 
Oa knee cartilage. 
Methylation of the 5ʹUtr modulates the direction 
of rs143383 allelic imbalance
We have previously shown that the aeI of rs143383 is 
increased after aZa induced demethylation of GDF5 in 
the heterozygous sW872 human liposarcoma cell line 
(reynard et al. 2011). However, aZa globally demethyl-
ates Dna and so this may be an indirect effect due to aZa-
induced expression changes in trans-acting factors that 
regulate the allelic imbalance rather than demethylation of 
GDF5. to further explore how Dna methylation modu-
lates the genetic effect of rs143383, we analysed the effect 
of 5ʹUtr methylation on the imbalance between the C and 
t alleles. the 5ʹUtr was cloned into the CpG-free lucif-
erase vector pCpGl, in vitro methylated and transfected 
into sW1353 human chondrosarcoma and sW872 cells. 
When unmethylated, the C allele pCpGl-5ʹUtr plasmid 
had significantly higher luciferase activity relative to the t 
allele in sW1353 (C/T ratio of 1.18, p = 0.0026, Fig. 4a) 
and sW872 (C/T ratio of 1.46, p = 0.0003, Fig. 4b) cell 
lines, similar to the level of allelic imbalance of rs143383 
observed in synovial joint tissues (egli et al. 2009). Dna 
methylation had a larger repressive effect on the promoter 
activity of the C allele pCpGl-5ʹUtr construct than the t 
allele construct, resulting in the inverted C/T allelic ratio of 
0.7 in sW1353 (p < 0.0001, Fig. 4c) and 0.59 in sW872 
cells (p < 0.0001, Fig. 4d). 
Methylation affects the binding of sP1 and sP3 
to rs143383 in an allele-specific manner
to elucidate how Dna methylation modulates the level 
and direction of allelic imbalance of rs143383, we exam-
ined the effect that methylation of the +37 CpG site has on 
transcription factor binding to rs143383. this CpG site is 
located 4 bp upstream of rs143383 within the sP1/sP3 con-
sensus site and is demethylated in sW872 cells after aZa 
treatment concomitant with increased allelic imbalance of 
rs143383 (reynard et al. 2011). eMsas were performed 
with double-stranded probes encompassing the +37 CpG 
site and rs143383, and unlabeled unmethylated competitor 
C and t allele oligonucleotides (Fig. 5a). a lower Dna–
protein complex and two upper-protein complexes were 
observed with both unmethylated C and t allele probes in 
nuclear lysates from the sW872 cells (arrows in Fig. 5b–d) 
and we have previously shown that these complexes con-
tain the sP1 and sP3 transcription factors (syddall et al. 
2013). In agreement with our previous report, we found 
that the protein complexes bound more strongly to the 
unmethylated t allele probe of rs143383 than the C allele 
probe (Figure s2a). this was also observed when nuclear 
extracts from HaCs as well as sW1353 chondrosarcoma 
and MG63 osteosarcoma cell lines were used (data not 
Fig. 2  Inhibition of Dna methylation is associated with increased 
GDF5 expression in human articular chondrocytes (HaCs). a effect 
of aZa treatment on GDF5 expression. HaCs from four Oa patients 
were cultured in 5 µM aZa dissolved in 50 % acetic acid or 50 % 
acetic acid alone (control) for three passages and gene expression 
measured after the third passage. b GDF5 expression in HaCs trans-
fected with sirnas against the Dna methyltransferase enzymes 
and the non-targeting control sirna. Four wells of a 96-well plate 
were transfected per sirna for three independent experiments. the 
percentage of sirna-mediated inhibition of expression relative to 
the control sirna is stated for each enzyme. GDF5 expression lev-
els were normalised to 18s and control-treated cells and those trans-
fected with the control sirna given an arbitrary value of 1. Error 
bars denote standard error of the mean. *p < 0.05, **p < 0.01, Mann–
Whitney U test
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shown). Methylation of the C allele of rs143383 and +37 
CpG site alone or in combination had little or no effect on 
protein complex binding to the C allele probe (Fig. 5b), 
with the same concentration of unlabelled unmethylated 
C allele competitor required to outcompete binding of all 
four probes. However, methylation of the +37 CpG site 
did affect the avidity of protein binding to the t allele of 
rs143383 (Fig. 5c), with a higher concentration of unmeth-
ylated t allele competitor required to inhibit the forma-
tion of the unmethylated Dna–protein complexes relative 
to the methylated Dna–protein complexes. this effect 
of +37 methylation on binding to the t allele probe was 
also observed when an sP1/sP3 consensus competitor was 
used, with binding to the methylated t probe outcompeted 
at a lower competitor concentration relative to the unmeth-
ylated t probe (Fig. 5d). Furthermore, the supershifted 
protein complexes formed upon addition of an anti-sP1 
antibody (Fig. 5e) or anti-sP3 antibody (Fig. 5f) were 
fainter when the methylated t allele probe was incubated 
with sW872, sW1353, MG63 or HaC nuclear extracts 
Fig. 3  Methylation of the 
GDF5 locus in nOF, Oa 
hip and Oa knee cartilage. 
Methylation was assessed by 
pyrosequencing of bisulphite 
converted genomic Dna. a 
schematic diagram of the 
GDF5 CpG island and 5ʹUtr. 
the CpG island spans from 
−1,345 to −1,210 bp upstream 
of the GDF5 tss and contains 
nice CpG sites. the 5ʹUtr is 
located from +1 to +315 bp. b 
Percentage overall methylation 
of the CpG island in cartilage 
from nOF (n = 19), Oa hip 
(n = 11) and Oa knee (n = 13) 
patients. c Methylation of the 
CpG island by CpG site. d total 
methylation of five CpG sites 
within the 5ʹUtr in cartilage 
from nOF (n = 19), Oa hip 
(n = 13) and Oa knee (n = 16) 
patients. e Methylation of the 
5ʹUtr by CpG site. f Meth-
ylation of the CpG site created 
by the C allele of rs143383 in 
cartilage from patients homozy-
gous (CC) or heterozygous (Ct) 
for this allele. nOF = 11 Ct 
and 2 CC; Oa hip = 8 Ct and 
2 CC; Oa knee = 8 Ct and 2 
CC. Bars in b, d and f represent 
the mean and the error bars in c 
and e denote standard devia-
tion. *p < 0.05, **p < 0.01, 
***p < 0.001, one-way anOva 
with Bonferroni correction for 
multiple testing
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compared to the supershifted complexes formed with the 
unmethylated t allele probe. together these data indi-
cate that sP1 and sP3 bind more avidly to the t allele of 
rs143383 in vitro when the +37 CpG site is unmethylated 
than when this site is methylated. 
sP1, sP3, sUB1 and DeaF1 repress GDF5 promoter 
activity in an allele- and methylation-dependent manner
We have previously shown that sP1, sP3, and DeaF1 
repress GDF5 expression, with the t allele of rs143383 
being repressed more than the C allele, leading to the aeI 
observed at rs143383 (syddall et al. 2013). Given that 
methylation of the 5ʹUtr alters the direction of this allelic 
imbalance and that methylation of the +37 CpG site within 
the sP1/sP3 consensus sequence abrogates binding of 
these proteins to the t allele of rs143383 in vitro, as shown 
above, the role of methylation in allele-specific repression 
of rs143383 by sP1, sP3 and DeaF1 was further exam-
ined. sW1353 cells were co-transfected with a methylated 
or unmethylated 5ʹUtr pGl3 enhancer luciferase plasmid, 
an eGFP vector containing the open reading frames (OrF) 
of sP1, sP3 or DeaF1 and the ptK-rl Renilla plasmid. 
the luciferase readings were normalised against Renilla 
and plotted as a percentage of the values obtained from 
the co-transfection of the relevant 5ʹUtr plasmid with the 
empty eGFP vector.
there was a statistically significant interaction between 
plasmid methylation and genotype on the effect of 
sP1 overexpression on GDF5 5ʹUtr promoter activ-
ity (F1,55 = 11.55, p = 0.001). as expected based on the 
eMsa results, sP1 overexpression repressed the unmeth-
ylated t allele more strongly than the unmethylated C 
allele (p < 0.0001; Fig. 6a). However, when the 5ʹUtr was 
methylated, sP1 repressed both alleles to approximately 
the same extent and had no effect on the allelic ratio. Meth-
ylation had a differential effect on the two alleles, with 
reduced repression of the methylated t allele relative to the 
unmethylated t allele by sP1 overexpression (91 vs 82 %, 
p = 0.033) and increased repression of the C allele by sP1 
when methylated (87 vs 97 %, p = 0.011). 
there was no significant interaction between methyla-
tion and genotype when sP3 was overexpressed, although 
both methylation (F1,52, p = 0.006) and genotype (F1,52, 
p < 0.0001) had a significant effect on promoter activity 
individually. sP3 overexpression significantly decreased 
the promoter activity of both alleles when the 5ʹUtr was 
unmethylated, with greater repression of the t allele than 
the C allele plasmid (p = 0.002; Fig. 6b). surprisingly, 
the promoter activity of both alleles was more strongly 
repressed by sP3 overexpression when methylated 
(C = 75 % and T = 65 % when methylated, and C = 88 % 
and T = 72 % when unmethylated), but this was not sig-
nificant for the t allele. although the t allele was more 
Fig. 4  effect of Dna methylation on the promoter activity of GDF5 
5ʹUtr. a and b luciferase activity of unmethylated pCpGl-5ʹUtr 
plasmids with either a t allele or C allele at rs143383 after transfec-
tion into (a) sW1353 chondrosarcoma and (b) sW872 liposarcoma 
cells. c and d Promoter activity of in vitro methylated pCpGl-5ʹUtr 
transfected into (c) sW1353 cells and (d) sW872 cells. luciferase 
values were normalised to Renilla activity and data shown are the 
mean ± standard deviation for three independent experiments (n = 6) 
per cell line. **p < 0.01, ***p < 0.001, Mann–Whitney U test
Fig. 5  Methylation of the +37 CpG site affects binding of sP1 
and sP3 proteins to rs143383. a schematic diagram of the double-
stranded DY682-labelled rs143383 probes and unlabelled rs143383 
competitors used for eMsa. Open circles represent unmethyl-
ated CpG dinucleotides and solid circles represent methylated CpG 
sites. b effect of methylation on protein binding to the C allele 
of rs143383. Five, 10-, 25- and 50-fold molar excess of unlabelled 
C allele competitor was added to the binding reaction as indicated. 
c effect of +37 CpG methylation on formation of rs143383 t allele 
and C allele protein-Dna complexes. d Competition eMsas with 
double-stranded oligonucleotides containing the consensus sequence 
for sP1/sP3. For B-D, eMsas were performed with nuclear extracts 
from the sW872 cell line, which is heterozygous for rs143383, 
whilst the arrows indicate the rs143383-protein complexes that are 
formed. e and f sP1 and sP3 supershift eMsas. addition of (e) an 
anti-sP1 and (f) an anti-sP3 antibody resulted in supershifting of the 
rs143383-protein complexes (indicated by arrowheads) relative to a 
control antibody in sW872, sW1353 chondrosarcoma, MG63 osteo-
sarcoma and HaCs nuclear protein lysates
▸
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strongly repressed by sP3 irrespective of methylation sta-
tus, the differential repression of the two alleles was dimin-
ished by methylation.
the strongest repression of the unmethylated 5ʹUtr 
promoter activity was observed when DeaF1 was 
overexpressed, with the t allele preferentially repressed 
(Fig. 6c). Methylation significantly reduced the DeaF1-
mediated repression of the GDF5 5ʹUtr (F1,128, 
p < 0.0001), and methylation abrogated the differential 
repression of the C and t alleles.
1066 Hum Genet (2014) 133:1059–1073
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We previously reported that the transcriptional co-acti-
vator sUB1 (P15) binds to the GDF5 5ʹUtr and interacts 
with sP1, sP3 and DeaF1 (syddall et al. 2013). although 
modulating sUB1 protein levels had no effect on GDF5 
expression in that report, we had hypothesised that it acts 
as a linker between the sP1/sP3/DeaF1 complex and the 
general transcriptional machinery. We thus examined here 
what effect sUB1 had on promoter activity of the 5ʹUtr 
when this region is methylated. this revealed that there was 
a significant interaction between methylation and geno-
type on the effect of sUB1 overexpression (F1,118 = 13.22, 
p < 0.0001). Confirming our previous observations, sUB1 
had no effect on the promoter activity of the unmethylated 
5ʹUtr plasmids irrespective of genotype (Fig. 6d). How-
ever, when the 5ʹUtr was methylated, sUB1 overexpres-
sion differentially regulated the two alleles of rs143383, 
increasing the promoter activity of the C allele by 25 % 
(p < 0.0001) and suppressing the activity of the t allele 
plasmid.
these results clearly demonstrated that the impact that 
the four trans-acting factors have on gene expression at the 
allelic level is modulated by the methylation status of the 
GDF5 5ʹUtr.
Materials and methods
tissue collection
Macroscopically normal articular cartilage samples were 
obtained from patients with nOF fracture with no history 
of Oa and from Oa patients undergoing joint replacement 
of the hip (total hip replacement, tHr) or the knee (total 
knee replacement, tKr). the radiological stage of Oa 
was a Kellgren and lawrence grade of 2 or more. Cases of 
inflammatory arthritis, post-traumatic or post-septic arthri-
tis were excluded. no cases suggestive of skeletal dyspla-
sia or developmental dysplasia were included. tissue was 
obtained with informed donor consent and newcastle and 
north tyneside ethics Committee approval (reC reference 
number 09/H0906/72).
Human chondrocyte isolation, aZa treatment and rna 
interference
Primary human chondrocytes (HaCs) were isolated by 
enzymatic digestion of Oa cartilage and cultured as 
described previously (Bui et al. 2012). Cells were seeded 
in 25 cm2 flasks, and were cultured for one population 
doubling before being cultured in the presence of 5 µM 
5-aza-2ʹdeoxycytine (aZa; sigma–aldrich) dissolved 
in 50 % acetic acid or vehicle alone (50 %v/v acetic acid) 
for three population doublings. Fresh aZa was added 
to the cultures every 2 days during the time course of the 
experiment. at the end of each population doubling, cells 
were washed once in PBs and half of the cells harvested 
for nucleic acid extraction (see below). For sirna experi-
ments, 10,000 HaCs were seeded per well of a 96-well 
plate overnight and then transfected with smartPool sir-
nas targeted against DNMT1 (Dharmocon, thermo scien-
tific, UK), DNMT3A (Qiagen), DNMT3B (Dharmocon) and 
siControl (Dharmocon) as described by Zhang et al., 2008. 
three days post transfection cDna was synthesised using 
the Cells-to-cDna II kit (Invitrogen) and GDF5 expres-
sion was assessed by quantitative real-time rt-PCr as 
described below.
Fig. 6  Methylation status influences the effect sP1, sP3, sUB1 and 
DeaF1 have on promoter activity. Unmethylated and in vitro methyl-
ated C luciferase vectors containing the GDF5 C or t allele 5ʹUtr 
were cotransfected into sW1353 cells with (a) sP1-eGFP, (b) sP3-
eGFP, (c) sUB1-eGFP or (d) DeaF1-eGFP plasmids and the con-
trol prl-tK Renilla plasmid. luciferase values were normalised 
to Renilla and are plotted as a percentage relative to the control co-
transfection of the empty eGFP plasmid with the relevant unmethyl-
ated or methylated C or t allele 5ʹUtr vector. Data shown are the 
mean ± standard error for four independent experiments (n = 5) per 
cell line. a 2-way anOva was performed to test for methylation, 
differences between the alleles and their interaction. Pairwise com-
parisons were performed using Fisher’s lsD test to compare the four 
groups, *p < 0.05, **p < 0.01, ***p < 0.001
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nucleic acid extraction
Following aZa treatment, nucleic acids were extracted 
from cells grown in monolayer using the Omega eZna 
total Dna/rna isolation kit (r6731-02; Omega Bio-
tek) following the manufacturer’s instructions. Cartilage 
samples were collected, snap-frozen in liquid nitrogen and 
stored at −80 °C until nucleic acid extraction. after fro-
zen tissue was ground under liquid nitrogen using a retsch 
mixer mill 200 (retsch limited, leeds, UK), genomic 
Dna and rna were extracted as above using a protocol 
established for human tissue.
qrt-PCr and genotyping
total rna was reverse transcribed using the superscript 
First-strand synthesis system (Invitrogen) and GDF5 
expression analysed by quantitative real-time rt-PCr. 
GDF5 expression was normalised to the level of 18S gene 
expression using the calculation 2−ΔCt. Genotyping of 
rs143383 was performed on cartilage Dna samples using 
a taqMan snP Genotyping assay (applied Biosystems). 
Primers are listed in table 1. 
Dna methylation analysis by pyrosequencing
Cartilage genomic Dna was bisulphite converted using 
the epitect Bisulfite kit (Qiagen) according to the manu-
facturer’s instructions. the methylation status of the GDF5 
CpG island and 5ʹUtr was assayed by quantitative bisul-
phite pyrosequencing of PCr-amplified regions as previ-
ously described (reynard et al. 2011). two independent 
PCr replicates were performed per sample and the biotin-
labelled products sequenced using the PyroMark Q96 MD 
Table 1  list of primers and 
probes used in this study
the bold and underlined bases 
in the eMsa probes indicate 
the position of rs143383. the 
series of underlined bases in the 
sP1/sP3 competitors indicate 
the site of the consensus 
sequence for sP1/sP3
FP forward primer, RP reverse 
primer, SP sequencing primer, 
Pr probe, me methylated
Method Primer sequence
Pyrosequencing
 CpG island FP: 5ʹ-tGtGttaaGttGtttaGGGGtttta-3ʹ
rP: 5ʹ-aCtaCaatCtCtaCCtCCCaaattC-biotin-3ʹ
sP: 5ʹ-aatattatGtGGGaaattGt-3ʹ
 5ʹUTR FP: 5ʹ-ttGGaGtatataGGtaGtatta-3ʹ
rP: 5ʹ-tCCCCtaaaatCtCtaaC-biotin-3ʹ
sP: 5ʹ-ttaGttGtGtaGGaGaaaGG-3ʹ
GDF5 expression FP: 5ʹ-CtGtGattCCaGGaGtGCaG-3ʹ
rP: 5ʹ-atCCtCttCattGaCtCtGCC-3ʹ
Pr: 5ʹ-CCaCGaCCatGtCCtC-3ʹ
rs143383 genotyping FP: 5ʹ-aGtCaGttGtGCaGGaGaaaGG-3ʹ
rP: 5ʹ-GCaGCtGaaaataaCtCGttCttGaa-3ʹ
Pr: 5ʹ-aGaaaGCCaCCGCC-3ʹ
DY-682 eMsa probes
 rs143383 C allele unmethylated FP: 5ʹ-GaGaaaGGGGGCGGtCGGCtttCtCC-3ʹ
rP: 5ʹ-GGaGaaaGCCGaCCGCCCCCtttCtC-3ʹ
 rs143383 C allele methylated FP: 5ʹ-GaGaaaGGGGGCmeGGtCGGCtttCtCC-3ʹ
rP: 5ʹ-GGaGaaaGCCGaCCmeGCCCCCtttCtC-3ʹ
 rs143383 t allele unmethylated FP: 5ʹ-GaGaaaGGGGGCGGtTGGCtttCtCC-3ʹ
rP: 5ʹ-GGaGaaaGCCAaCCGCCCCCtttCtC-3ʹ
 rs143383 t allele methylated FP: 5ʹ-GaGaaaGGGGGCmeGGtTGGCtttCtCC-3ʹ
rP: 5ʹ-GGaGaaaGCCAaCCmeGCCCCCtttCtC-3ʹ
sP1/sP3 consensus competitor FP: 5ʹ-aattGGGGGGGCGGGGGtaCGtaGCa-3ʹ
rP: 5ʹ-tGCtaCGtaCCCCCGCCCCCCCaatt-3ʹ
Cloning into pGl3-enhancer FP: 5ʹ-GGGGaCtaGtGGattCaaaaCtaGGGGG-3ʹ
rP: 5ʹ-GGGGaaGCttCCGCtGaatGaCaCCaaaG-3ʹ
Cloning into eGFP-n1
 sP1 FP: 5ʹ-GGGGGaattCatGGatGaaatGaCaGCtGtG-3ʹ
rP: 5ʹ-GGGGCCGCGGGaaGCCattGCCaCtGatatt-3ʹ
 sP3 FP: 5ʹ-GGGGGaattCatGaCCGCtCCCGaaaaGCCC-3ʹ
rP: 5ʹ-GGGGCCGCGGCtCCattGtCtCatttCCaGa-3ʹ
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system. Pyro Q CpG 1.0.6 software was used to exclude 
samples that did not pass the bisulphite conversion criteria 
and to quantify methylation.
pCpGl in vitro methylation and transient transfection
the GDF5-pCpGl plasmid generated previously (reynard 
et al. 2011) contains the GDF5 5ʹUtr encompassing the 
rs143383 and rs143384 snPs ligated into the CpG dinu-
cleotide-free pCpGl luciferase reporter plasmid (Klug and 
rehli 2006). two plasmid haplotypes were generated, one 
with a C allele at rs143383 and rs143384 (GDF5-pCpGl-C) 
and a second with a t allele at both snPs (GDF5-pCpGl-
t). 10 µg of plasmid Dna was in vitro methylated as previ-
ously described (reynard et al. 2011) using the CpG meth-
yltransferase M.SssI (new england Biolabs, Hitchin, UK). 
sW1353 chondrosarcoma cells and sW872 liposarcoma 
cells were seeded as described (reynard et al. 2011) and co-
transfected for 24 h with 500 ng of the appropriate pCpGl 
vector and 30 ng of the control prl-tK Renilla vector (Pro-
mega, southampton, UK) using exGen 500 in vitro transfec-
tion reagent (Fermentas, York, UK). luciferase and renilla 
activity was assayed using the Dual luciferase assay sys-
tem (Promega) and a MicrolUMat Plus lB96v luminome-
ter (Berthold technologies). three independent experiments 
were performed with six wells transfected per construct.
eMsas
nuclear proteins were extracted from sW872 liposar-
coma, sW1353 chondrosarcoma, MG63 osteosarcoma and 
HaCs as previously described (syddall et al. 2013). single-
stranded DY682-labelled oligonucleotides spanning +26 to 
+51 relative to the GDF5 tss were synthesised by euro-
fins MWG Operon and then annealed to generate double-
stranded probes (syddall et al. 2013). six probe combina-
tions were generated that contained either the C allele or 
t allele at rs143383 and were unmethylated or methyl-
ated at the +37 CpG site and rs143383 CpG site. Binding 
reactions were performed for 20 min at room temperature 
using the Odyssey eMsa buffer kit (licor Biosciences) 
containing 5 µg nuclear protein, 200 fmol labelled probe, 
1× Binding Buffer, 2.5 mM Dtt, 0.25 % tween-20, 
1 μg Poly (dI:dC; Invitrogen), and 5 mM MgCl2. samples 
were separated on a 5 % (w/v) native polyacrylamide gel 
in 0.5 × tBe for 4 h at 100 v followed by visualisation 
with the Odyssey infrared imager (licor Biosciences). For 
competition assays, unlabelled oligonucleotides identical 
to the unmethylated probes or oligonucleotides contain-
ing the sP1/sP3 transcription factor consensus sequence 
were added to the binding reaction in excess. all probe and 
competitor sequences are given in table 1. For supershift 
assays, 2 µg of either anti-sP1 (santa Cruz Biotechnology; 
sc-59) or anti-sP3 (sc-644) antibody was added to the bind-
ing reaction.
GDF5-pCpGl and peGFP-n1 co-transfections
the sP1, sP3 and sUB1 OrFs were amplified from cDna 
and inserted into the EcorI and SacII restriction sites of the 
peGFP-n1 plasmid (Clontech) to create sP1-eGFP, sP3-
eGFP and sUB1-eGFP plasmids. the DeaF1-eGFP-n1 
plasmid was kindly donated by CG Fathman (Yip et al. 
2009). the GDF5 region spanning −93 to +304 relative 
to the tss and encompassing the 5ʹUtr was inserted 
into the MluI and BglII sites of the pGl3-enhancer plas-
mid (Promega) to create rs143383 C and t allele 5ʹUtr-
pGl3 enhancer plasmids. Primer sequences are listed in 
table 1. 5ʹUtr-pGl3 plasmids were in vitro methylated 
as above. sW1353 cells were seeded as described (rey-
nard et al. 2011) and co-transfected with 500 ng of sP1-
eGFP or sP3-eGFP plasmid, 500 ng of rs143383 C allele 
or t allele 5ʹUtr-pGl3 enhancer plasmid and 30 ng of 
the control prl-tK Renilla vector (Promega, southamp-
ton, UK) using exGen 500 in vitro transfection reagent. 
empty eGFP-n1 and pGl3 enhancer plasmids were used 
as a control. Five wells were transfected per condition and 
four independent experiments were performed. after 24 h, 
luciferase and renilla readings were assayed as above, nor-
malised to the eGFP-n1 and pGl3 control plasmids.
statistical analyses
For two-way analyses, a Mann–Whitney U test was used. 
For three-way analyses, a one-way analysis of variants 
(anOva) test was used. Both tests were performed using 
GraphPad Prism software and the p value was Bonferroni 
corrected to account for multiple testing. For four-way 
analyses, a two-way anOva was performed using sPss 
version 21. an omnibus test was performed testing for 
methylation, genotype, and their interaction, and if this was 
statistically significant (p value <0.05), pairwise compari-
sons were performed using Fisher’s least significant Dif-
ference (lsD) test. raw p values are reported unadjusted 
for multiplicity.
Discussion
In this study, we investigated the interaction between genet-
ics, Dna methylation and transcription at the Oa suscep-
tibility snP rs143383. We initially discovered that GDF5 
expression is higher in Oa compared to non-Oa cartilage, 
and higher in knee compared to hip cartilage. We then dem-
onstrated that a reduction of DnMt enzyme levels or activ-
ity by sirna knock-down or aZa treatment respectively 
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led to a significant increase in GDF5 expression in patient 
chondrocytes, suggesting that Dna methylation regulates 
GDF5 expression in the cells that are pivotal to the Oa dis-
ease process.
DnMt enzymes catalyse the transfer of a methyl group 
to the cytosine in a CpG dinucleotide to maintain Dna 
methylation patterns during cell division and to establish 
new patterns of methylation during development and dif-
ferentiation (Jones 2012). DnMt1 and DnMt3a predomi-
nate in cartilage (sesselmann et al. 2009), and expression 
of DnMt1 is reduced in Oa cartilage (Hashimoto et al. 
2009), although there are no changes in global methylation 
levels (sesselmann et al. 2009). Inhibition or loss of DnMt 
enzymes results in passive demethylation due to failure to 
methylate the newly synthesised Dna strand to re-establish 
methylation patterns. Dna methylation inhibits transcrip-
tion by preventing the binding of methylation-sensitive tran-
scription factors and by the formation of inactive chromatin 
through the action of methyl-binding proteins and chroma-
tin remodelling complexes. thus, the increased chondro-
cyte GDF5 expression associated with aZa- and sirna-
mediated promoter demethylation presumably results from 
increased binding of transcription factors that are inhib-
ited by methylation and through prevention of binding by 
methyl-binding proteins such as MeCP1 and MeCP2. It is 
also possible that the levels of proteins that regulate GDF5 
expression are altered in these cells, and aZa treatment has 
previously been reported to decrease levels of sP3, a tran-
scriptional repressor of GDF5, in human and mice cells 
(lee et al. 2004; Wang et al. 2003).
We next looked at methylation of the GDF5 CpG island 
and 5ʹUtr in osteoarthritic cartilage. Changes in promoter 
methylation have been associated with aberrant expression 
of several genes in Oa cartilage including the transcription 
factor SOX9 (Kim et al. 2013), and several matrix degrad-
ing enzymes (roach et al. 2005). We observed increased 
expression of GDF5 in Oa cartilage and this was accom-
panied by demethylation of several CpG sites within the 
GDF5 CpG island. Oa knee cartilage was hypomethylated 
relative to Oa hip and control hip cartilage in both the CpG 
island and the 5ʹUtr, including the site created by the C 
allele of rs143383, demonstrating that there are epige-
netic differences at the GDF5 locus between osteoarthritic 
hip and knee cartilage. to our knowledge, this is the first 
study to compare methylation patterns between cartilage 
from different joints and the differences we observed at the 
GDF5 locus may reflect global differences in Dna meth-
ylation patterns between cartilages from different joints. 
such differential methylation by skeletal site could partly 
explain why there is a limited overlap between the genes 
aberrantly expressed in Oa hip and Oa knee cartilage (Xu 
et al. 2012). the methylation differences between Oa and 
control cartilage in the CpG island and between Oa knee 
and hip cartilage in the 5ʹUtr are only small (3–12 %) 
but are similar to those observed at the MMP13 and SOX9 
promoters in Oa and control hip cartilage (Bui et al. 2012; 
Kim et al. 2013). Furthermore, several recent studies have 
demonstrated that, unlike in cancer, disease-associated 
methylation differences are small for complex diseases. For 
example, methylation level differences between monozy-
gotic twins discordant for disease range from 0.3 to 6.6 % 
in type I diabetes (rakyan et al. 2011), 4–9 % in schizo-
phrenia and bipolar disorder (Dempster et al. 2011), and 
from <1–8 % in psoriasis (Gervin et al. 2012).
Dna polymorphisms can influence methylation of 
nearby CpG sites, leading to differences in methylation 
levels between alleles, a phenomenon termed allele-spe-
cific methylation (asM; schalkwyk et al. 2010; Meaburn 
et al. 2010), with the associated Dna variant referred to 
as a methylation quantitative trait locus (methQtls). 
methQtls are common in the human genome and may 
result in allelic differences in gene expression (Zhang et al. 
2010; Gibbs et al. 2010; Bell et al. 2011; tycko 2010). One 
example is the rs13121031 snP located within the alter-
native promoter of the cerebellar ataxia-associated gene 
TRPC3. the C allele of this snP has decreased methyla-
tion of surrounding CpG sites relative to the G allele in 
several tissues and this correlates with increased expression 
of the C allele relative to the G allele in brain Martin-tru-
jillo et al. 2011). It has been proposed that rs143383 may 
act in a similar manner to rs13121031 to affect methyla-
tion of nearby CpG sites, and thus gene expression (Bar-
ter and Young 2013). However, we found no evidence that 
rs143383 genotype affects methylation at any of the CpG 
sites within the GDF5 CpG island or 5ʹUtr, although we 
cannot rule out that rs143383 may influence CpG sites out-
side of these two regions or that rs143383 may act as an 
methQtl in other tissues.
In our previous study, we observed that aZa-induced 
demethylation increased the expression imbalance between 
the C and t alleles of rs143383, which suggested that Dna 
methylation can modulate the functional effect of rs143383 
on the GDF5 promoter (reynard et al. 2011). In the current 
study, we used in vitro methylation combined with lucif-
erase assays to confirm this observation and to determine if 
the effect of methylation on rs143383 is direct or indirect. 
as expected, there was increased promoter activity of the 
C allele relative to the t allele when the luciferase plas-
mid was unmethylated. However, hypermethylation of the 
5ʹUtr inverted the direction of the imbalance at rs143383 
such that the methylated t allele construct had significantly 
increased promoter activity compared to the methylated C 
allele construct. Furthermore, this data demonstrated that 
the effect of methylation on rs143383 is intrinsic to the 
5ʹUtr rather than an indirect effect, such as altered expres-
sion of trans-acting factors.
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the methylation of Dna binding sites is known to 
inhibit the binding of transcription factors (Kim et al. 2013; 
Bui et al. 2012), with the altered expressions of MMP13 
and SOX9 in Oa hip cartilage resulting from changes in 
methylation affecting the binding of the transcriptional 
factor CreB to the MMP13 and SOX9 promoters. Dna 
methylation therefore represents a mechanism that could 
modulate the allelic expression of rs143383. Using eMsa 
and overexpression assays, we thus examined the effect 
of 5ʹUtr methylation on the binding and activity of sP1, 
sP3, sUB1 and DeaF1, all of which bind to and repress 
the GDF5 5ʹUtr (syddall et al. 2013).
the sP1/sP3 binding site (GGGGGCGGtC/t) 
spans both rs143383 and the +37 CpG site located 4 bp 
upstream, which is significantly hypomethylated in Oa 
knee cartilage. Both proteins bind with higher affinity 
to the t allele of rs143383 than the C allele in an eMsa 
assay (syddall et al. 2013), despite the t allele being more 
divergent in sequence to the sP1/sP3 consensus binding 
site of GGGGCGGGG. Methylation of the +37 CpG site, 
the CpG site created by the C allele at rs143383 or both 
sites has little or no effect on sP1 or sP3 binding on the 
background of the C allele at rs143383. However, methyla-
tion of the +37 site abrogates the binding of both proteins 
when the t allele is present at rs143383, such that these 
proteins bind with less affinity to the methylated t allele 
than the methylated or unmethylated C allele. these results 
clearly indicate that the strength of sP1 and sP3 binding to 
rs143383 is both allele and methylation dependent.
Co-transfection of luciferase constructs with an sP1 
overexpression vector confirmed that 5′Utr methylation 
reduces sP1-mediated transcriptional repression of the t 
allele of rs143383. However, sP1 repressed the C allele of 
rs143383 more strongly when methylated; this was unex-
pected given that methylation of the +37 CpG had no 
effect on sP1 binding in eMsas. One explanation for this 
could be that methylation of additional CpG sites within 
the 5′Utr outside of the sP1/sP3 site also affect sP1 
binding. surprisingly, overexpression of sP3 repressed 
both alleles more strongly when methylated than when 
unmethylated, although the allelic difference in repres-
sion was reduced by methylation. Given that sP1 and sP3 
compete for binding sites, it is possible that reduced bind-
ing of endogenous sP1 to the methylated C and t alleles 
combined with the increased sP3/sP1 ratio may increase 
the number of cells in which sP3 can bind over rs143383, 
even though the affinity of sP3 binding is reduced by 
methylation. as we have previously reported (syddall 
et al. 2013), when the 5ʹUtr is unmethylated, DeaF1 
preferentially represses the t allele of rs143383 leading to 
allelic imbalance in luciferase activity. Methylation abro-
gates the repressive effects of DeaF1 on the 5′Utr, and 
affects the t allele more strongly than the C allele causing 
the abolition of rs143383 imbalance. Whereas sUB1 over-
expression has no effect on either allele when unmethyl-
ated, methylation resulted in allele-specific affects on 
promoter activity, with reduced activity of the t allele but 
increased activity of the C allele. these results indicate 
that the strength of trans-activator binding to and tran-
scriptional repression of rs143383 is both methylation and 
allele dependent. In light of our findings, we propose the 
following model. When the +37 site is unmethylated, sP1, 
sP3 and DeaF1 proteins bind more avidly to the t allele 
of rs143383, repressing expression of the t allele relative 
to the C allele, resulting in an imbalance in favour of the 
C allele similar to that observed in joint tissues. However, 
when the +37 site is methylated, sP1, sP3 and DeaF-1 
binding affinity to the methylated t allele is reduced rela-
tive to the methylated C allele. this leads to an increased 
transcriptional de-repression of the t allele relative to the 
C, and the allelic imbalance at rs143383 is reduced or even 
reversed.
numerous studies have shown that the effect of Dna 
methylation on binding of sP1 and sP3 to the Dna is 
dependent on the binding site sequence, interacting pro-
teins and cell type. Methylation has no effect on sP1 bind-
ing to the CLDN4 promoter (Honda et al. 2006) or sP1/sP3 
consensus binding site (Höller et al. 1988), whereas meth-
ylation within the consensus sequence inhibits sP1 binding 
to the Cadm1 gene (reamon-Buettner and Borlak 2008), 
and methylation adjacent to, but not within the sP1 site, 
reduces sP1 binding at the p21Cip1 promoter (Zhu et al. 
2003). Methylation also has variable effects on sP3 bind-
ing affinity, with methylation inhibiting binding of sP3 to 
the chondrocyte-specific ChM-1 promoter (aoyama et al. 
2004), leading to gene repression. In contrast, methylation 
increases binding of sP3 and the methyl-binding protein 
MBD2 to the mouse δ-Opioid receptor (mDOR) promoter 
(Wang et al. 2003), and sP3 can recruit chromatin remodel-
ling proteins leading to gene repression (Won et al. 2002). 
as well as altering binding affinity, methylation can also 
alter the function of sP3, with sP3 increasing the sP1-
mediated activity of the unmethylated mDOR promoter but 
inhibiting sP1-mediated promoter activity of the methyl-
ated mDOR promoter (Wang et al. 2003). a similar mecha-
nism may occur at rs143383, with methylation increasing 
the repressive activity of sP3 despite reducing sP3 bind-
ing affinity, and this could explain why sP3 represses the 
methylated 5′Utr luciferase plasmid more strongly than 
the unmethylated plasmid.
In our previous study, we suggested that differences 
in GDF5 5ʹUtr Dna methylation could explain the 
intra- and inter-individual differences in allelic imbal-
ance of rs143383 observed in joint tissues from individ-
uals with Oa. In the present study, we have uncovered 
the molecular mechanism by which Dna methylation 
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modulates the allelic expression of rs143383 and dis-
covered that Oa knee cartilage is hypomethylated rela-
tive to both normal and Oa hip cartilage. these differ-
ences in 5ʹUtr methylation, especially at the +37 CpG 
site, could explain why rs143383 is an Oa susceptibil-
ity allele particularly for the knee compared to the hip in 
europeans. In addition, differences in methylation levels 
between different joint tissues could underlie the differ-
ent odds ratios (Ors) for the different pathologies associ-
ated with rs143383. the Or for rs143383 in knee Oa is 
1.17 but the snP has larger effect sizes on congenital hip 
dysplasia (Or 1.37; rouault et al. 2010) and lumbar disc 
degeneration (Or 1.72; Williams et al. 2011)). Further-
more, ethnic differences in GDF5 methylation as a result 
of different environmental and genetic factors could 
account for the disparity between the Ors of rs143383 
in european and asians; rs144383 has an Or of 1.53 
in knee Oa in a thai population (tawonsawatruk et al. 
2011) and an Or of 1.79 in a Japanese cohort (Chapman 
et al. 2008). One area of future research to confirm these 
hypotheses will therefore be to examine GDF5 5ʹUtr 
methylation and aeI of rs143383 in joint tissues from the 
different pathologies, and in cartilage from Oa patients 
of different ethnic backgrounds.
to conclude, we have found that the Oa susceptibility 
gene GDF5 is regulated by Dna methylation in cartilage 
from patients and that aberrant methylation correlates with 
increased GDF5 expression. Methylation of the 5ʹUtr 
modulates the functional effects of the Oa polymorphism 
rs143383 on GDF5 gene expression through interfer-
ing with the binding of transcriptional repressor proteins 
including sP1 and sP3 in an allele-specific manner. Fur-
thermore, the +37 CpG site within the sP1 and sP3 bind-
ing site is hypomethylated in knee cartilage relative to hip 
cartilage and we hypothesise that differential methylation 
of this site may be responsible for the joint specific effect 
of the rs143383 snP on Oa susceptibility.
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